Clinical Trials
16 trialsNCT00923507 2026-06-05
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
National Institutes of Health Clinical Center (CC)
Recruiting
NCT01683279 2026-06-05
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT07624799 2026-06-03
PACIFIC
French Innovative Leukemia Organisation
Phase 2 Not yet recruiting
NCT05557695 2026-06-02
EPIC
AstraZeneca
Recruiting
NCT01087294 2026-06-01
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT07509151 2026-06-01
SOUNDTRACK-C1
AstraZeneca
Phase 3 Recruiting
NCT05442515 2026-05-28
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07511426 2026-05-28
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
Phase 1 Not yet recruiting
NCT04728893 2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05362773 2026-05-22
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT03573700 2026-05-20
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT02787369 2026-05-19
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03774654 2026-05-18
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
Phase 1 Active not recruiting
NCT06651970 2026-05-18
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
Phase 4 Recruiting
NCT06564038 2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2 Recruiting
NCT07342478 2026-05-14
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc
Phase 3 Recruiting